
    
      The study consist of 4 study visits, including Screening/Baseline Visit 1 (Day 0, which is
      anticipated to be the same date as Visit 6 in F301 or F302) and visits after 1, 2 and 3
      months of treatment (Visits 2-4).

      Primary:

      The primary objective of the study is to evaluate the safety of TNX-102 SL tablets taken
      daily at bedtime over an additional 3 months in patients with FM who have completed the
      double-blinded lead-in study

      Secondary:

      The secondary objective is to evaluate the efficacy of TNX-102 SL tablets taken daily at
      bedtime to control symptoms of FM
    
  